<DOC>
	<DOC>NCT02262143</DOC>
	<brief_summary>Efficacy and safety of combination therapy of rosuvastatin and fenofibrate versus rosuvastatin monotherapy in mixed dyslipidemia patients: A randomized, multi-center, double-blind, phase 3 study</brief_summary>
	<brief_title>Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>19 ~ 80 years old High risk patient to Coronary Heart Disease At Visit 1(Screening) 1. Treated with Rosuvastatin 10mg monotherapy 4weeks prior to this study 2. 110 mg/dl ≥ LDLC, 200 mg/dl ≤ TG ≤ 500 mg/dl At Visit 2 (Baseline), 110 mg/dl ≥ LDLC, 200 mg/dl ≤ TG ≤ 500 mg/dl AST or ALT &gt; 2X ULN Patients with uncontrolled hyperthyroidism (TSH&gt;1.5X ULN) Patients with uncontrolled diabetes (HbA1c ≥ 9%) Patients with uncontrolled hypertension(SBP&gt;160mmHg or DBP&gt;95mmHg) Patients with congestive heart failure(NYHA class III~IV) or uncontrolled arrhythmia within 6 months Patients treated with any investigational drugs within 3 months at the time consents are obtained Not eligible to participate for the study at the discretion of investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>